Rigel Pharma (RIGL) Reports In-Line Q1 Loss

Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $5 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM